StreetInsider.com News Articles

Form 8-K ADMA BIOLOGICS, INC. For: Jun 02

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591573.html

Form 8-K ADMA BIOLOGICS, INC. For: Jun 02

Tue, 02 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260602/26591573.html

Form 4 ADMA BIOLOGICS, INC. For: May 27 Filed by: Grossman Jerrold B

Thu, 28 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260528/26567193.html

Form 4 ADMA BIOLOGICS, INC. For: May 27 Filed by: Grossman Jerrold B

Thu, 28 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260528/26567193.html

Form 4 ADMA BIOLOGICS, INC. For: May 12 Filed by: Grossman Jerrold B

Thu, 14 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26489680.html

Form 4 ADMA BIOLOGICS, INC. For: May 12 Filed by: Grossman Jerrold B

Thu, 14 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260514/26489680.html

Form 4 ADMA BIOLOGICS, INC. For: May 11 Filed by: Grossman Jerrold B

Tue, 12 May 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260512/26479441.html

Form 4 ADMA BIOLOGICS, INC. For: May 11 Filed by: Grossman Jerrold B

Tue, 12 May 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260512/26479441.html

ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation

Mon, 11 May 2026 13:47:00 -0400

Boston, Massachusetts--(Newsfile Corp. - May 11, 2026) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.

What is this all about?

ADMA Biologics stock fell over 24% in after-hours trading on May 6, 2026, after the company withdrew its long-term financial guidance, citing evolving U.S. plasma products and immunoglobulin market competitive dynamics. The disclosure followed a prior Culper Research report alleging that ADMA's

ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation

Mon, 11 May 2026 13:47:00 -0400

What is this all about?

ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors

Thu, 07 May 2026 09:16:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA).

On May 6, 2026, ADMA Biologics reported that "[b]eginning in the second half of 2025 and continuing into the first quarter of 2026, new FDA-approved IVIG products, and other pharmaceutical products which compete with certain IVIG product uses, entered the market with aggressive pricing tactics, including extended payment terms, rebates and discounts. This has led to increases in raw material plasma supply and finished goods inventory

ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors

Thu, 07 May 2026 09:16:00 -0400

ADMA Biologics Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Thu, 07 May 2026 08:20:00 -0400

Boston, Massachusetts--(Newsfile Corp. - May 7, 2026) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.

What is this all about?

ADMA Biologics Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Thu, 07 May 2026 08:20:00 -0400

What is this all about?

ADMA Biologics (ADMA) PT Lowered to $20 at Mizuho

Thu, 07 May 2026 06:49:45 -0400

Mizuho analyst Anthony Petrone lowered the price target on ADMA Biologics (NASDAQ: ADMA) to $20.00 (from $24.00) while maintaining a Outperform rating.

ADMA Biologics (ADMA) PT Lowered to $18 at Canaccord

Thu, 07 May 2026 06:38:17 -0400

Canaccord analyst Gary Nachmann lowered the price target on ADMA Biologics (NASDAQ: ADMA) to $18.00 (from $21.00) while maintaining a Buy rating.

Form 10-Q ADMA BIOLOGICS, INC. For: Mar 31

Wed, 06 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260506/26445496.html

Form 10-Q ADMA BIOLOGICS, INC. For: Mar 31

Wed, 06 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260506/26445496.html

ADMA Biologics (ADMA) Misses Q1 EPS by 1c, Offers Guidance

Wed, 06 May 2026 16:50:16 -0400

ADMA Biologics (NASDAQ: ADMA) reported Q1 EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $114.5 million versus the consensus estimate of $142.74 million.

GUIDANCE:

ADMA Biologics sees FY2026 revenue of $530-560 million, versus the consensus of $630 million.

FY 2026 total revenue expected to be $530 million to $560 million
FY 2026 Adjusted Net Income expected to be $170 million to $200 million
FY 2026 Adjusted EBITDA expected to be $265 million to $300 million
Withdrawing previously provided long-term guidance due to current competitive dynamics in the PDT & IG market

For earnings history and earnings-related data

ADMA Biologics (ADMA) Misses Q1 EPS by 1c, Offers Guidance

Wed, 06 May 2026 16:50:16 -0400

GUIDANCE:

ADMA Biologics sees FY2026 revenue of $530-560 million, versus the consensus of $630 million.

FY 2026 total revenue expected to be $530 million to $560 million
FY 2026 Adjusted Net Income expected to be $170 million to $200 million
FY 2026 Adjusted EBITDA expected to be $265 million to $300 million
Withdrawing previously provided long-term guidance due to current competitive dynamics in the PDT & IG market

For earnings history and earnings-related data

Form 8-K ADMA BIOLOGICS, INC. For: May 06

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443846.html

Form 8-K ADMA BIOLOGICS, INC. For: May 06

Wed, 06 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260506/26443846.html

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

Wed, 06 May 2026 16:05:00 -0400

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year

1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year

1Q 2026 Adjusted Net Income⁽¹⁾ of $40.7 Million, 22% Year-Over-Year Growth

1Q 2026 Adjusted EBITDA⁽²⁾ of $59.7 Million, Representing 24% Year-Over-Year Growth

1Q 2026 Cash from Operations of $58 Million Highlights Strong Cash Generation

Strong Balance Sheet and Financial Flexibility Support Continued Execution

Reiterates Confidence in ASCENIV Growth Outlook Driven by Durable Demand Fundamentals

Updates FY 2026 Outlook and Withdraws Long-Term Guidance to Reflect Evolving

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

Wed, 06 May 2026 16:05:00 -0400

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year

1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year

1Q 2026 Adjusted Net Income⁽¹⁾ of $40.7 Million, 22% Year-Over-Year Growth

1Q 2026 Adjusted EBITDA⁽²⁾ of $59.7 Million, Representing 24% Year-Over-Year Growth

1Q 2026 Cash from Operations of $58 Million Highlights Strong Cash Generation

Strong Balance Sheet and Financial Flexibility Support Continued Execution

Reiterates Confidence in ASCENIV Growth Outlook Driven by Durable Demand Fundamentals

Updates FY 2026 Outlook and Withdraws Long-Term Guidance to Reflect Evolving

Form 8-K ADMA BIOLOGICS, INC. For: May 04

Mon, 04 May 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260504/26420845.html